Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Globe Newswire News Releases

May 14, 2024 08:00 ET
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the initiation of...
May 14, 2024 08:00 ET
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the...
May 14, 2024 08:00 ET
Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, today reported financial results for the quarter ended March 31, 2024 and provided a company update. “The progress across our portfolio in the...
May 14, 2024 08:00 ET
Optimi Health Receives Certificate of Analysis For MDMA 40mg and 60mg GMP Capsules
Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada-licensed GMP psychedelics pharmaceutical manufacturer specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to announce it has...
May 14, 2024 08:00 ET
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, today reported business updates and financial results for the first quarter...
May 14, 2024 08:00 ET
Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting
Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that clinical and non-clinical data on rose bengal photodynamic antimicrobial therapy (“RB PDAT”) were presented at the annual meeting of the...
May 14, 2024 08:00 ET
Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and...
May 14, 2024 08:00 ET
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced...
May 14, 2024 08:00 ET
Verifone and Logos in Strategic Partnership to Revolutionize Unattended Payments
Verifone, the payments architect shaping ecosystems for in-person and online commerce experiences, and Logos Payment Solutions, the pioneer in unattended payment technologies, today announce their strategic partnership to upgrade unattended...
May 14, 2024 08:00 ET
YPrime Appoints Lindsay Daniel as Chief Human Resources Officer
YPrime, the leading pioneer in clinical trial technology, today announced the appointment of Lindsay Daniel as Chief Human Resources Officer (CHRO). Daniel will lead YPrime's human resources strategy in this role, aligning people priorities with...
May 14, 2024 08:00 ET
Zacatecas Silver Provides Update at El Cristo, Zacatecas Property
Zacatecas Silver Corp. (“Zacatecas Silver” or the “Company”, ZAC:TSX Venture; ZCTSF: OTC Markets; 7TV: Frankfurt) is pleased to announce that the Company has completed additional field work at its Zacatecas Property. This has included a detailed...
May 14, 2024 07:55 ET
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today reported financial results for the first quarter ended March 31, 2024. “This...
May 14, 2024 07:45 ET
Global Technologies, Ltd. Announces Its Financial Results for the Quarter Ended March 31, 2024 and the Company’s Strategic Business Transition
Global Technologies, Ltd. (OTC: GTLL), a Delaware corporation, today announced its financial results for the quarter ended March 31, 2024, and provided an update on its strategic transition from real estate to a focused expansion into the...
May 14, 2024 07:35 ET
Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter
Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce the...
May 14, 2024 07:30 ET
2024 Rabbet Report: Risk Management and Automation Emerge as Top Priorities in Construction Finance
Rabbet, the leading provider of construction finance software, today released its highly anticipated 2024 State of Construction Finance Report. The annual report provides critical insights into the evolving dynamics of construction finance, this...
May 14, 2024 07:30 ET
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended March 31, 2024. "During the first quarter, we made significant strides in advancing both our...
May 14, 2024 07:30 ET
Alimera Sciences Reports First Quarter 2024 Results
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial...
May 14, 2024 07:30 ET
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental and neuropsychiatric disorders...
May 14, 2024 07:30 ET
Batteh Named Saia’s Chief Financial Officer
Saia, Inc. (Nasdaq: SAIA), a leading transportation provider offering national less-than-truckload (LTL), non-asset truckload, expedited and logistics services, today announced that Matthew Batteh has been promoted to Executive Vice President and...
May 14, 2024 07:30 ET
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Bank of America...